Hyperfine Inc (HYPR)

$1

-0.01

(-0.99%)

Market is closed - opens 7 PM, 04 Oct 2024

Performance

  • $0.96
    $1.02
    $1.00
    downward going graph

    3.53%

    Downside

    Day's Volatility :5.42%

    Upside

    1.96%

    downward going graph
  • $0.76
    $2.10
    $1.00
    downward going graph

    23.87%

    Downside

    52 Weeks Volatility :63.75%

    Upside

    52.38%

    downward going graph

Returns

PeriodHyperfine IncSector (Health Care)Index (Russel 2000)
3 Months
6.72%
7.5%
0.0%
6 Months
8.0%
6.9%
0.0%
1 Year
-43.46%
20.9%
0.0%
3 Years
-89.1%
21.0%
-21.1%

Highlights

Market Capitalization
75.5M
Book Value
$0.93
Earnings Per Share (EPS)
-0.58
Wall Street Target Price
1.23
Profit Margin
0.0%
Operating Margin TTM
-298.71%
Return On Assets TTM
-29.65%
Return On Equity TTM
-48.74%
Revenue TTM
11.9M
Revenue Per Share TTM
0.17
Quarterly Revenue Growth YOY
7.3999999999999995%
Gross Profit TTM
907.0K
EBITDA
-43.8M
Diluted Eps TTM
-0.58
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.57
EPS Estimate Next Year
-0.55
EPS Estimate Current Quarter
-0.14
EPS Estimate Next Quarter
-0.13

Analyst Recommendation

Buy
    77%Buy
    22%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Hyperfine Inc(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
6
6
Hold
2
3
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 23.0%

Current $1.00
Target $1.23

Technicals Summary

Sell

Neutral

Buy

Hyperfine Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Hyperfine Inc
Hyperfine Inc
8.54%
8.0%
-43.46%
-89.1%
-89.21%
Stryker Corporation
Stryker Corporation
0.46%
2.92%
35.88%
37.71%
69.5%
Boston Scientific Corp.
Boston Scientific Corp.
3.28%
23.0%
62.59%
97.59%
110.82%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-4.01%
-29.06%
-5.19%
-37.96%
-11.22%
Abbott Laboratories
Abbott Laboratories
-0.57%
2.45%
19.02%
-1.32%
40.63%
Medtronic Plc
Medtronic Plc
1.2%
5.92%
17.62%
-28.0%
-15.8%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Hyperfine Inc
Hyperfine Inc
NA
NA
NA
-0.57
-0.49
-0.3
NA
0.93
Stryker Corporation
Stryker Corporation
40.27
40.27
2.65
12.0
0.19
0.07
0.01
51.86
Boston Scientific Corp.
Boston Scientific Corp.
68.13
68.13
2.06
2.41
0.09
0.05
NA
13.85
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
25.98
25.98
3.51
2.63
0.22
0.12
NA
12.35
Abbott Laboratories
Abbott Laboratories
35.41
35.41
4.16
4.66
0.14
0.06
0.02
22.6
Medtronic Plc
Medtronic Plc
30.31
30.31
1.67
5.2
0.08
0.04
0.03
37.39
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Hyperfine Inc
Hyperfine Inc
Buy
$75.5M
-89.21%
NA
0.0%
Stryker Corporation
Stryker Corporation
Buy
$137.7B
69.5%
40.27
16.12%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$123.4B
110.82%
68.13
12.0%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$40.1B
-11.22%
25.98
23.74%
Abbott Laboratories
Abbott Laboratories
Buy
$198.4B
40.63%
35.41
13.65%
Medtronic Plc
Medtronic Plc
Buy
$115.5B
-15.8%
30.31
12.06%

Insights on Hyperfine Inc

  • Increasing Revenue

    Revenue is up for the last 4 quarters, 2.33M → 3.63M (in $), with an average increase of 13.7% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -9.84M → -10.15M (in $), with an average decrease of 3.1% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 62.6% return, outperforming this stock by 106.1%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 91.3% return, outperforming this stock by 180.4%

Institutional Holdings

  • Vanguard Group Inc

    4.37%
  • Fosun International Ltd

    2.40%
  • Avidity Partners Management LP

    1.64%
  • Alphabet Inc

    1.24%
  • BlackRock Inc

    0.90%
  • Geode Capital Management, LLC

    0.72%

Company Information

hyperfine’s mission is to make mri accessible to every patient, regardless of income or resources. anytime. anywhere.hyperfine’s swoop® portable mr imaging system™ addresses limitations of current imaging technologies. swoop wheels directly to a patient’s bedside, where it plugs into a standard electrical outlet and uses an apple ipad® for control. images display within minutes, enabling critical decision-making capabilities across various clinical settings such as neurointensive care units, emergency departments, pediatrics, and more. designed as a complementary system to fixed conventional mri systems, new users can be trained on system operation, device navigation, and safety in about 30 minutes, helping clinicians streamline workflow. the complete swoop™ portable mr imaging system costs less than the annual service contract for most fixed conventional mri systems.in august 2020, swoop received market-ready fda clearance for portable mr imaging of the brain and head for patients of

Organization
Hyperfine Inc
Employees
131
CEO
Mr. R. Scott Huennekens CPA, M.B.A.
Industry
Financial

FAQs